All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SARS-CoV-2 s-protein based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: BVX-0320
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Biovaxys
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 15, 2021
Details:
Under the terms of the agreement, WuXi Bio will synthesize high yields of fully characterized, Good Laboratory Practice (GLP) grade SARS-CoV-2 s-protein required by BioVaxys for BVX-0320, its COVID-19 vaccine candidate, and for its Covid-T™ immunodiagnostic program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AS1411
Therapeutic Area: Infections and Infectious Diseases Product Name: AS1411
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Qualigen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 05, 2020
Details:
Qualigen Therapeutics has signed a contract with STA Pharmaceutical, a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HLX71
Therapeutic Area: Infections and Infectious Diseases Product Name: HLX71
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2020
Details:
The Company actively involves in development of anti-COVID-19 drugs with two candidates in pre-clinical phase, including HLX71 (S1 protein), and HLX70 (S1 protein).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Institut of Butantan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 11, 2020
Details:
This collaboration focuses on the clinical development to advance the clinical trials of CoronaVac, Sinovac’s inactivated vaccine candidate against COVID-19 to Phase III.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Funding April 27, 2020
Details:
CEPI to provide funds to Clover Biopharmaceuticals Australia to support preparation and initiation of a phase 1 trial of Clover’s protein-based COVID-19 S-Trimer vaccine in Australia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
Details:
The pilot testing of the vaccine for novel coronavirus, will be focused on animal toxicology and the vaccine's effectiveness. Clinical trials are expected to start in mid-April.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 24, 2020
Details:
GSK will provide Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
